Suppr超能文献

Role of Serum Biomarkers in Early Detection of Non-Alcoholic Steatohepatitis and Fibrosis in West Virginian Children.

作者信息

Sodhi Komal, Bracero Lucas, Feyh Andrew, Nichols Alexandra, Srikanthan Krithika, Latif Tariq, Preston Deborah, Shapiro Joseph I, Elitsur Yoram

机构信息

Department of Surgery and Pharmacology, Joan C. Edwards School of Medicine, Marshall University, USA.

Department of Internal Medicine, Joan C. Edwards School of Medicine, Marshall University, USA.

出版信息

J Clin Cell Immunol. 2016 Feb;7(1). doi: 10.4172/2155-9899.1000393. Epub 2016 Feb 17.

Abstract

BACKGROUND

Obesity, an epidemic among West Virginia children, as well as insulin resistance (IR), is well-established contributors to nonalcoholic steatohepatitis (NASH). Progression of NASH can lead to hepatic fibrosis and cirrhosis, making early detection imperative. The standard for diagnosing NASH is histologically liver biopsy, which is highly invasive and generally contraindicated in children. By studying serum biomarkers associated with NASH, we aim to identify high risk children who can benefit from a less invasive, alternative approach to the early detection of NASH.

METHODS

Seventy one children were prospectively recruited and divided into 3 groups: . Serum samples were drawn for each patient and biomarker levels were assessed ELISA kits.

RESULTS

and patients had significantly elevated levels of lipid metabolism and accumulation markers (FGF-21, NEFA, FATP5, ApoB), oxidative stress markers (dysfunctional HDL, 8-Isoprostane), inflammatory markers(dysfunctional HDL, CK-18) and apoptosis markers (CK-18) compared to control patients (p<0.02). Bilirubin (an antioxidant) was significantly decreased in the and patients compared to control (p<0.02).

CONCLUSION

This study showed a correlation between obesity, IR, and biomarkers associated with NASH in pediatrics patients from West Virginia, with obese with IR patients showing the strongest correlation. These findings support the clinical application of these serum biomarkers as a less invasive method for early detection of NASH and hepatic fibrosis.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3739/4866601/fef0bc45737c/nihms769438f1.jpg

相似文献

1
Role of Serum Biomarkers in Early Detection of Non-Alcoholic Steatohepatitis and Fibrosis in West Virginian Children.
J Clin Cell Immunol. 2016 Feb;7(1). doi: 10.4172/2155-9899.1000393. Epub 2016 Feb 17.
3
Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
Am J Physiol Gastrointest Liver Physiol. 2019 Apr 1;316(4):G462-G472. doi: 10.1152/ajpgi.00358.2018. Epub 2019 Jan 17.
4
Features of nonalcoholic steatohepatitis in severely obese children and adolescents undergoing sleeve gastrectomy.
Surg Obes Relat Dis. 2017 Sep;13(9):1599-1609. doi: 10.1016/j.soard.2017.04.005. Epub 2017 Apr 7.
5
Correlation between insulin resistance and liver histology in patients with nonalcoholic steatohepatitis with and without obesity.
Indian J Gastroenterol. 2020 Feb;39(1):42-49. doi: 10.1007/s12664-020-01024-z. Epub 2020 Mar 28.
6
Vitamin D Status and Bone Mineral Density in Obese Children with Nonalcoholic Fatty Liver Disease.
J Korean Med Sci. 2015 Dec;30(12):1821-7. doi: 10.3346/jkms.2015.30.12.1821. Epub 2015 Nov 30.
9
Non-alcoholic steatohepatitis in children.
Pediatr Transplant. 2004 Dec;8(6):613-8. doi: 10.1111/j.1399-3046.2004.00241.x.
10
Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population.
Gastroenterol Hepatol. 2017 Jun-Jul;40(6):388-394. doi: 10.1016/j.gastrohep.2017.02.009. Epub 2017 Mar 28.

引用本文的文献

1
Fibroblast Growth Factor-21 as a Potential Therapeutic Target of Nonalcoholic Fatty Liver Disease.
Ther Clin Risk Manag. 2023 Jan 22;19:77-96. doi: 10.2147/TCRM.S352008. eCollection 2023.
2
Leukocyte cell-derived chemotaxin-2 and fibroblast growth factor 21 in alcohol-induced liver cirrhosis.
World J Hepatol. 2021 Dec 27;13(12):2071-2080. doi: 10.4254/wjh.v13.i12.2071.

本文引用的文献

1
Dysfunctional HDL and atherosclerotic cardiovascular disease.
Nat Rev Cardiol. 2016 Jan;13(1):48-60. doi: 10.1038/nrcardio.2015.124. Epub 2015 Sep 1.
2
Controversy in the diagnosis of pediatric non-alcoholic fatty liver disease.
World J Gastroenterol. 2015 Jun 7;21(21):6444-50. doi: 10.3748/wjg.v21.i21.6444.
3
Non-alcoholic fatty liver disease: The diagnosis and management.
World J Hepatol. 2015 Apr 28;7(6):846-58. doi: 10.4254/wjh.v7.i6.846.
4
Fatty Acids, Obesity and Insulin Resistance.
Obes Facts. 2015;8(2):147-55. doi: 10.1159/000381224.
5
Non-alcoholic Fatty liver disease in children.
Curr Health Sci J. 2014 Jul-Sep;40(3):170-6. doi: 10.12865/CHSJ.40.03.03. Epub 2014 Aug 4.
6
Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?
Mol Cell Endocrinol. 2015 Dec 15;418 Pt 1:55-65. doi: 10.1016/j.mce.2015.02.018. Epub 2015 Feb 24.
7
Biomarkers in nonalcoholic fatty liver disease.
Can J Gastroenterol Hepatol. 2014 Dec;28(11):607-18. doi: 10.1155/2014/757929.
8
The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy.
Metabolism. 2015 Mar;64(3):380-90. doi: 10.1016/j.metabol.2014.11.009. Epub 2014 Nov 28.
9
Mechanism linking diabetes mellitus and obesity.
Diabetes Metab Syndr Obes. 2014 Dec 4;7:587-91. doi: 10.2147/DMSO.S67400. eCollection 2014.
10
In vivo effects of polyunsaturated, monounsaturated, and saturated fatty acids on hepatic and peripheral insulin sensitivity.
Metabolism. 2015 Feb;64(2):315-22. doi: 10.1016/j.metabol.2014.10.019. Epub 2014 Oct 25.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验